A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions

NCT04645797 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

11

Enrollment

INDUSTRY

Sponsor class

Stopped Study terminated prematurely due to internal corporate decision

Conditions

Advanced Colorectal Carcinoma

Interventions

DRUG: APR003

Sponsor

Apros Therapeutics, Inc